trending Market Intelligence /marketintelligence/en/news-insights/trending/Sl8jhJKQ3TpujY4vzPk4XA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Neos Therapeutics settles patent case against Teva unit for ADHD drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Neos Therapeutics settles patent case against Teva unit for ADHD drug

Neos Therapeutics Inc. agreed to settle its patent infringement case filed against a unit of Teva Pharmaceutical Industries Ltd.

Neos filed a complaint in December 2017 with the U.S. District Court for the District of Delaware alleging that an abbreviated new drug application for the generic version of Cotempla XR-ODT, or methylphenidate, filed with the U.S. Food and Drug Administration by Teva unit Teva Pharmaceuticals USA Inc. infringed its patents.

Under the agreement, Neos has given Teva rights to manufacture and market the generic version of Cotempla XR-ODT starting in 2026 or earlier under certain circumstances.

Cotempla XR-ODT is approved by the FDA to treat attention deficit hyperactivity disorder in patients aged 6 to 17 years old.

Neos did not share any details of the agreement, which is subject to submission to the Federal Trade Commission and the U.S. Department of Justice.